Literature DB >> 23060474

Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered?

Paul F Pinsky1, Christine D Berg.   

Abstract

The National Lung Screening Trial (NLST) demonstrated a 20% reduction in lung cancer mortality for screening with low-dose computed tomography versus chest radiography. The major NLST eligibility criteria were age 55-74, a 30 + pack year smoking history and current smoking status or having quit in the last 15 years. We utilized data from SEER (Surveillance, Epidemiology and End Results), the United States (US) Census and the National Health Interview Survey, as well as two statistical models of lung cancer risk, to estimate the proportion of the total US population and of those currently diagnosed with lung cancer that would be covered by the NLST and other suggested eligibility criteria. For the NLST criteria, 26.7% of lung cancers and 6.2% of the population (over 40) were covered. A criterion of ever smokers aged 50-79 would cover 68% of the cancers while screening 30% of the (over 40) population. To extend recommended screening beyond the NLST eligibility criteria, two questions are key. First, can the 20% mortality reduction observed in NLST be extrapolated to populations at moderately lower risk? Second, given that such an extrapolation is valid, what background incidence rate is high enough for the balance between the benefits and harms of screening to be favourable? Further research on these questions is needed.

Entities:  

Mesh:

Year:  2012        PMID: 23060474     DOI: 10.1258/jms.2012.012010

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  54 in total

Review 1.  Principles of Cancer Screening.

Authors:  Paul F Pinsky
Journal:  Surg Clin North Am       Date:  2015-06-20       Impact factor: 2.741

2.  Improving selection criteria for lung cancer screening. The potential role of emphysema.

Authors:  Pablo Sanchez-Salcedo; David O Wilson; Juan P de-Torres; Joel L Weissfeld; Juan Berto; Arantzazu Campo; Ana B Alcaide; Jesús Pueyo; Gorka Bastarrika; Luis M Seijo; Maria J Pajares; Ruben Pio; Luis M Montuenga; Javier J Zulueta
Journal:  Am J Respir Crit Care Med       Date:  2015-04-15       Impact factor: 21.405

Review 3.  Lung cancer screening-low dose CT for lung cancer screening: recent trial results and next steps.

Authors:  Emma Louise O'Dowd; David R Baldwin
Journal:  Br J Radiol       Date:  2017-10-17       Impact factor: 3.039

4.  Improving CT screening for lung cancer with a highly predictive risk model.

Authors:  Cristiano Rampinelli; Marta Minotti
Journal:  Ann Transl Med       Date:  2018-04

5.  Lung cancer screening: the path forward.

Authors:  Caroline Chiles; Reginald F Munden
Journal:  Transl Lung Cancer Res       Date:  2018-06

Review 6.  Computed tomography screening for lung cancer in the National Lung Screening Trial: a cost-effectiveness analysis.

Authors:  William C Black
Journal:  J Thorac Imaging       Date:  2015-03       Impact factor: 3.000

7.  Risk models to select high risk candidates for lung cancer screening.

Authors:  Matthew B Schabath
Journal:  Ann Transl Med       Date:  2018-02

Review 8.  Implementing lung cancer screening in the real world: opportunity, challenges and solutions.

Authors:  Robert J Optican; Caroline Chiles
Journal:  Transl Lung Cancer Res       Date:  2015-08

Review 9.  Lung cancer screening in patients with chronic obstructive pulmonary disease.

Authors:  Jessica Gonzalez; Marta Marín; Pablo Sánchez-Salcedo; Javier J Zulueta
Journal:  Ann Transl Med       Date:  2016-04

10.  Perceptions and Utilization of Lung Cancer Screening Among Primary Care Physicians.

Authors:  Dan J Raz; Geena X Wu; Martin Consunji; Rebecca Nelson; Canlan Sun; Loretta Erhunmwunsee; Betty Ferrell; Virginia Sun; Jae Y Kim
Journal:  J Thorac Oncol       Date:  2016-06-23       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.